Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients

Abstract

Purpose

Here, we sought to develop a PET radioligand based on trastuzumab labeled with 124I, 124I-trastuzumab, to evaluate its distribution, internal dosimetry, and initial PET images of HER2-positive lesions in gastric cancer (GC) patients.

Methods

In animal studies, micro-PET imaging and bio-distribution were performed to examine the specificity of 124I-trastuzumab in HER2-positive and HER2-negative mouse models. Subsequently, 124I-trastuzumab was applied in human clinic trial. Six gastric cancer patients with metastases underwent 124I-trastuzumab PET imaging, with 18F-FDG PET/CT in each to compare.

Results

In animal studies, PET imaging of 124I-trastuzumab showed significant higher tumor uptake than that of 124I-IgG1 in HER2-positive PDX mouse models at 24 h. The low tumor uptake of 124I-trastuzumab in HER2-negative PDX models further confirmed the specificity. In human clinical studies, 18 HER2-positive lesions and 11 HER2-negative lesions were evaluated in PET imaging analysis. The detection sensitivity of 124I-trastuzumab was 100% (18/18) at 24 h. The PET images showed significant difference in tumor uptake between HER2-positive and HER2-negative lesions at 24 h (SUVmax 7.83 ± 0.55 vs. 1.75 ± 0.29, p < 0.0001). Quite striking difference in tumor uptake was observed between 124I-trastuzumab and 18F-FDG (SUVmax 1.75 ± 0.29 vs. 6.46 ± 0.44, p < 0.0001) in HER2-negative lesions, further confirming the specific binding of 124I-trastuzumab in HER2-positive lesions. The radiation-absorbed dose was calculated to be 0.3011 ± 0.005 mSv/MBq. No toxicities or adverse effects were observed in any of the patients.

Conclusion

The findings described here demonstrated that 124I-trastuzumab was feasible to detect HER2-positive lesions in primary and metastatic gastric cancer patients and to differentiate HER2-positive and HER2-negative lesions quantitatively.

Graphic abstract

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

HER2:

Human epidermal receptor type 2

GC:

Gastric cancer

GEC:

Gastroesophageal junction cancer

IHC:

Immunohistochemistry

i.v.:

Intravenous injection

h :

Hour

SISH/CISH/FISH:

Silver, chromogenic, or fluorescent in situ hybridization

SPECT:

Single-photon emission computed tomography

PET:

Positron emission tomography

DFO:

Desferrioxamine

NOTA:

S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid

PDX:

Patient-derived tumor xenograft

radio-TLC:

Radioactive thin-layer chromatography scanner

HPLC:

High-performance liquid chromatography

p.i.:

Post-injection

d :

Day

SUVmax:

The maximum single-voxel standardized uptake value

ROIs:

Regions of interest

%ID/g:

Percent injected dose per gram

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67(1):7.

    Article  Google Scholar 

  2. 2.

    Lin S, Yan-Shen S, Huang-Ming H, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535–47.

    Article  Google Scholar 

  3. 3.

    Van CE, Sagaert X, Topal B, et al. Gastric cancer. J Natl Cancer Inst. 2016;57(1):2654–64.

    Google Scholar 

  4. 4.

    Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015;33(16):1760–9.

    CAS  Article  Google Scholar 

  5. 5.

    Stella M, Serventi A, Friedman D. Right portal vein thrombosis after splenectomy for trauma. J Gastrointest Surg. 2005;9(5):646–7.

    Article  Google Scholar 

  6. 6.

    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

    CAS  Article  Google Scholar 

  7. 7.

    Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46(11):1949–59.

    CAS  Article  Google Scholar 

  8. 8.

    Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6):593–9.

    Article  Google Scholar 

  9. 9.

    Pectasides D, Gaglia A, Arapantonidadioti P, et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res. 2006;26(1B):647.

    CAS  PubMed  Google Scholar 

  10. 10.

    Altundag K. Role of endocrine therapy in weak estrogen/progesterone receptor expression in HER2 negative breast cancer. Eur J Surg Oncol. 2018;44(4):539.

    Article  Google Scholar 

  11. 11.

    Altundag K. Digital breast tomosynthesis findings may be different in HER2 positive breast cancer patients according to hormone receptor status. Br J Radiol. 2018;91(1082):20170730.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87–100.

    Article  Google Scholar 

  13. 13.

    Chao WR, Lee MY, Ruan A, et al. Assessment of HER2 status using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques in mucinous epithelial ovarian cancer: a comprehensive comparison between ToGA biopsy method and ToGA surgical specimen method. PLoS ONE. 2015;10(11):e0142135.

    Article  Google Scholar 

  14. 14.

    Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24(15):2276–82.

    CAS  Article  Google Scholar 

  15. 15.

    Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50(6):974–81.

    CAS  Article  Google Scholar 

  16. 16.

    Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586–92.

    CAS  Article  Google Scholar 

  17. 17.

    Tamura K, Kurihara H, Yonemori K, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54(11):1869–75.

    CAS  Article  Google Scholar 

  18. 18.

    Kurihara H, Hamada A, Yoshida M, et al. (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015;5:8.

    Article  Google Scholar 

  19. 19.

    Woo SK, Jang SJ, Seo MJ, et al. Development of 64Cu-NOTA-Trastuzumab for HER2 targeting: radiopharmaceutical with improved pharmacokinetics for human study. J Nucl Med. 2018. https://doi.org/10.2967/jnumed.118.210294.

    Article  PubMed  Google Scholar 

  20. 20.

    Guo X, Zhu H, Zhou N, et al. Noninvasive detection of HER2 expression in gastric cancer by (64)Cu-NOTA-trastuzumab in PDX mouse model and in patients. Mol Pharm. 2018;15(11):5174–82.

    CAS  Article  Google Scholar 

  21. 21.

    Knowles SM, Zettlitz KA, Richard T, et al. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med. 2014;55(3):452–9.

    CAS  Article  Google Scholar 

  22. 22.

    Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304–10.

    CAS  Article  Google Scholar 

  23. 23.

    Hamilton EP, Patel MR, Armstrong AC, et al. A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR +/HER2- advanced breast cancer. Clin Cancer Res. 2018.

  24. 24.

    Chen Z, Huang W, Tian T, et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol. 2018;11(1):20.

    Article  Google Scholar 

  25. 25.

    Wong JYC, Raubitschek A, Yamauchi D, et al. A Pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother Radiopharm. 2010;25(4):387.

    CAS  Article  Google Scholar 

  26. 26.

    O’Donoghue JA, Lewis JS, Pandit-Taskar N, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med Off Publ Soc Nucl Med. 2017. https://doi.org/10.2967/jnumed.117.194555.

    Article  Google Scholar 

  27. 27.

    Van Dongen GA, Visser GW, Lub-de Hooge MN, et al. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12(12):1379–89.

    Article  Google Scholar 

Download references

Funding

The current research was financially supported by the National Key Research and Development Program of China (No. 2017YFC1308900), National Natural Science Foundation of China (81571705, 81671733, and 81871386), Beijing Municipal Administration of Hospitals-Yangfan Project (ZYLX201816), Beijing Natural Science Foundation, Jing-Jin-Ji special projects for basic research cooperation (H2018206600), Beijing Nova Program (Z171100001117020), and Beijing Excellent Talents Funding (2017000021223ZK33).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Zhi Yang or Hua Zhu.

Ethics declarations

Conflicts of interests

The authors declare no potential conflict of interests.

Ethical approval

All procedures in this study were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later versions. Informed consent, or its equivalent, was obtained from all patients included in the study. The clinical study was approved by the Ethics Committee of the Beijing Cancer Hospital (Ethics Approval License: 2018KT48).

Human and animal rights

All institutional and national guidelines for the care and use of laboratory animals were followed.

Informed consent

Informed consent was obtained from the 6 individual participants included in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 642 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guo, X., Zhou, N., Chen, Z. et al. Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. Gastric Cancer 23, 614–626 (2020). https://doi.org/10.1007/s10120-019-01035-6

Download citation

Keywords

  • 124I-trastuzumab
  • PET/CT
  • Gastric cancer
  • HER2